Clinical Trials

Multiple clinical trials spanning Early Phase 1 to Phase 3 evaluate the therapeutic application of isosorbide mononitrate across cardiovascular and obstetric conditions. Research led by academic centers and public health institutions—such as Al-Azhar University, Benha University, Assistance Publique - Hôpitaux de Paris, and the National Heart, Lung, and Blood Institute—focuses on heart failure with preserved ejection fraction, unexplained recurrent pregnancy loss, isolated idiopathic oligohydramnios, and cervical maturation or labor management in prolonged pregnancies among nulliparous women. Recruitment status across these protocol records includes both completed studies and those with an unknown status.

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT05341856 Unknown status
Recurrent Pregnancy Loss
Al-Azhar University
2022-05-01 Early Phase 1
NCT02053493 Completed
Heart Failure
Adrian Hernandez|National Heart Lung and Blood Institute (NHLBI)|Mayo Clinic|University of Vermont|Duke University
2014-04 Phase 2
NCT02712125 Completed
Isolated (Idiopathic) Oligohydramnios
Benha University
2013-08 Phase 2|Phase 3
NCT00930618 Completed
Prolonged Pregnancy|Nulliparity
Assistance Publique - Hôpitaux de Paris
2009-06 Phase 3

(data from https://clinicaltrials.gov, updated on 2024-05-22)

Check the Isosorbide Mononitrate product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Isosorbide mononitrate acts as an organic nitrate donor that undergoes enzymatic conversion to release free nitric oxide, which subsequently stimulates soluble guanylate cyclase to elevate intracellular cyclic guanosine monophosphate levels and induce vascular smooth muscle relaxation. This systemic vasodilation decreases cardiac preload and afterload, providing the functional basis for its clinical investigation in heart failure as well as in modulating uteroplacental hemodynamics for pregnancy-related conditions such as recurrent pregnancy loss and oligohydramnios.

Appendix RUO and cGMP Quality Standards

Quality Dimension RUO (Research Use Only) cGMP (Current Good Manufacturing Practice)
Clinical Applicability Prohibited in human clinical trials or medical diagnostics. Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status Non-regulated grade; exempt from drug manufacturing laws. Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment Unclassified analytical or research laboratories. Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control Basic purity and activity testing. Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation Basic equipment calibration; no process validation required. Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance Vendor self-declared without required formal QMS. Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact High risk of IND rejection if used as a critical raw material. Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).

Jump to

Note: Technical data last updated: Sep 1, 2026.